Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

► Outcomes for uterine papillary serous carcinoma (UPSC) are poor. ► Carboplatin and paclitaxel followed by radiotherapy is safe and tolerated well. ► Quality of life remains stable throughout this radical treatment.